rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs.
|
20498063 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumorigenic role of BRAF(V600E) in the development of PTC was documented in thyroid-targeted BRAF(V600E) transgenic mice, and rat thyroid cells overexpressed with BRAF(V600E) suggested that BRAF(V600E) is an initiator of tumorigenesis and is required for tumor progression in PTC.
|
20230995 |
2010 |
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras(G12D) activation and do not show a potent tumor suppressor response.
|
22532587 |
2012 |
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The EGFR resistance mutation T790M should be monitored at cancer progression.
|
31445213 |
2019 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR.
|
29069959 |
2017 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression.
|
28170370 |
2017 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression.
|
26577492 |
2016 |
rs351855
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression.
|
26675719 |
2015 |
rs351855
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This LOH involved the FGFR4-WT allele as frequently as the cancer progression-associated FGFR4-G388R polymorphic allele.
|
21037081 |
2010 |
rs758272654
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.
|
21156401 |
2010 |
rs758272654
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers.
|
20027678 |
2009 |
rs758272654
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015).
|
16467086 |
2006 |
rs351855
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used.
|
14710228 |
2004 |
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The single nucleotide polymorphism AURKA T91A (rs2273535) (Phe21Ile) has been identified as functional alternator of this kinase, the Ile allele is associated with the occurrence of chromosome segregation errors and tumor progression.
|
28647900 |
2018 |
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
For esophageal cancer, the AurkA Phe31-Ile polymorphism has previously been associated with tumor progression.
|
29560108 |
2018 |
rs3761548
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our study suggests that <i>FOXP3</i> polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression.
|
29731666 |
2018 |
rs1284806277
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Stable S100P knockdown CRC cell lines were established to elucidate the relationship between S100P expression and tumor progression in vitro and in vivo.
|
26975699 |
2016 |
rs3761548
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Stratified data also revealed an association of homozygous mutant genotype with advanced stage of tumor in premenopausal women (OR = 4.56; 95% CI = 1.07-19.38; p = 0.04) with disease duration of <6 months (OR = .10; 95% CI = 1.80-20.50; p = 0.002) suggestive of modulating effect of rs3761548 in tumor progression.
|
24338714 |
2014 |
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We crossed IL-6(-/-) mice with Kras(G12D) mutant mice, which develop lung tumors after activation of mutant Kras(G12D), to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo.
|
24260500 |
2013 |
rs752021744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression.
|
22684718 |
2012 |